Iterum Therapeutics PLC (NASDAQ:ITRM) Short Interest Up 205.0% in March

Iterum Therapeutics PLC (NASDAQ:ITRM) saw a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling 9,352,607 shares, a growth of 205.0% from the March 15th total of 3,065,983 shares. Approximately 17.9% of the company’s stock are sold short. Based on an average daily volume of 77,354,571 shares, the short-interest ratio is currently 0.1 days.

Iterum Therapeutics Stock Performance

NASDAQ:ITRM remained flat at $0.03 during mid-day trading on Monday. The stock has a market capitalization of $1.60 million, a P/E ratio of -0.04 and a beta of 2.96. Iterum Therapeutics has a 52 week low of $0.03 and a 52 week high of $1.42. The firm’s 50 day moving average price is $0.18 and its 200-day moving average price is $0.38.

Analyst Ratings Changes

Several brokerages have recently weighed in on ITRM. Weiss Ratings restated a “sell (e+)” rating on shares of Iterum Therapeutics in a research report on Monday, December 22nd. Maxim Group lowered shares of Iterum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 4th. Finally, HC Wainwright cut shares of Iterum Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, March 30th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $9.00.

Institutional Trading of Iterum Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. OneDigital Investment Advisors LLC grew its position in Iterum Therapeutics by 18.6% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock worth $128,000 after purchasing an additional 30,000 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Iterum Therapeutics in the third quarter valued at about $32,000. Jane Street Group LLC purchased a new stake in shares of Iterum Therapeutics in the second quarter valued at about $92,000. Alchemi Wealth LLC acquired a new stake in shares of Iterum Therapeutics during the fourth quarter worth about $90,000. Finally, Apollon Financial LLC boosted its stake in shares of Iterum Therapeutics by 151.8% during the fourth quarter. Apollon Financial LLC now owns 630,250 shares of the company’s stock worth $211,000 after buying an additional 380,000 shares during the period. Hedge funds and other institutional investors own 9.21% of the company’s stock.

About Iterum Therapeutics

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).